Log in
Enquire now
‌

US Patent 11802161 Anti-CD25 for tumour specific cell depletion

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11802161
Patent Inventor Names
Sergio Quezada
Pascal Merchiers
Kevin Moulder
Bianka Prinz
Beatriz Goyenechea Corzo
Josephine Salimu
Anne Goubier
Mark Brown
...
Date of Patent
October 31, 2023
Patent Application Number
16979929
Date Filed
March 13, 2019
Patent Citations
‌
US Patent 10745485 Anti-CD25 antibody agents
‌
US Patent 8486398 Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds
‌
US Patent 10738125 Anti-CD25 antibody agents
‌
US Patent 10752691 Anti-CD25 antibody agents
Patent Primary Examiner
‌
Julie Wu
Patent abstract

The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11802161 Anti-CD25 for tumour specific cell depletion

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.